Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Ionis Pharmaceuticals (IONS) -- Ignore unavailable to you. Want to Upgrade?

To: sds who wrote (2051)	6/26/1998 11:29:00 AM
From: marc ultra	Read Replies (1) \| Respond to of 4676

The news may be enough to wean ISIP from the ventilator but it is still in intensive care with a guarded prognosis

To: sds who wrote (2051)	6/26/1998 11:54:00 AM
From: Perry	Read Replies (1) \| Respond to of 4676

Yes you are right, I am confusing the two. Can you explain the difference? Thanks, Perry

To: sds who wrote (2051)	6/29/1998 10:48:00 AM
From: Scott H. Davis	Respond to of 4676

FYI, there has been concern that there may not be much of a market for CMV Ret. due to the efficacy of protease inhibitors. Read an article recently that indicates trouble in the making. Patients on long term inhibitors, especially multiples are coming up with some significant side effects, one of which was termed a "protease bubble". CDC is aware and gathering data. Does not appear to be tied to a specific PI. Bad news for those with HIV, possibly good news for ISIP. Scott